Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of "Moderate Buy" by Analysts

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.53.

Several research firms recently weighed in on LUNG. Piper Sandler reaffirmed an "overweight" rating and set a $9.00 price objective (down previously from $10.00) on shares of Pulmonx in a research report on Thursday, May 1st. D. Boral Capital reissued a "buy" rating and issued a $17.00 target price on shares of Pulmonx in a report on Thursday, May 1st. Canaccord Genuity Group dropped their target price on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Citigroup dropped their target price on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Finally, Morgan Stanley initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an "equal weight" rating for the company.

Pulmonx Price Performance

LUNG traded down $0.11 on Wednesday, hitting $3.03. 179,455 shares of the stock were exchanged, compared to its average volume of 311,311. Pulmonx has a 12 month low of $2.83 and a 12 month high of $9.37. The business has a 50-day moving average of $3.94 and a two-hundred day moving average of $5.84. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The firm has a market capitalization of $121.98 million, a price-to-earnings ratio of -2.10 and a beta of 0.52.

Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.01. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The business had revenue of $22.54 million during the quarter, compared to analysts' expectations of $22.03 million. Sell-side analysts forecast that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In related news, Director Glendon E. French III sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total value of $157,000.00. Following the completion of the transaction, the director now owns 991,974 shares in the company, valued at $7,786,995.90. This trade represents a 1.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard Ferrari sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $3.16, for a total transaction of $25,280.00. Following the completion of the transaction, the director now owns 87,024 shares of the company's stock, valued at approximately $274,995.84. This trade represents a 8.42% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,388 shares of company stock valued at $293,044. 6.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Parkman Healthcare Partners LLC raised its holdings in Pulmonx by 194.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock valued at $4,118,000 after buying an additional 404,022 shares during the last quarter. PDT Partners LLC increased its position in Pulmonx by 45.1% during the 1st quarter. PDT Partners LLC now owns 71,637 shares of the company's stock valued at $482,000 after purchasing an additional 22,259 shares during the period. Trexquant Investment LP increased its position in Pulmonx by 140.0% during the 1st quarter. Trexquant Investment LP now owns 224,909 shares of the company's stock valued at $1,514,000 after purchasing an additional 131,209 shares during the period. Informed Momentum Co LLC acquired a new stake in Pulmonx during the 1st quarter valued at approximately $668,000. Finally, Nuveen LLC acquired a new stake in Pulmonx during the 1st quarter valued at approximately $1,336,000. Institutional investors own 91.04% of the company's stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.